Results 61 to 70 of about 6,346 (180)

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Marathons and myasthenia gravis: a case report

BMC Neurology, 2018
Background The cardinal symptoms of auto-immune myasthenia gravis are fatigue and weakness. Endurance events such as marathon running would seem incompatible with this chronic disease. Many patients stop sport altogether.
Simone Birnbaum, Tarek Sharshar, Bruno Eymard, Marie Theaudin, Pierre Portero, Jean-Yves Hogrel   +5 more
doaj   +1 more source

Miasthenia gravis in pediatric age

Acta Médica del Centro, 2008
Background: Myasthenia gravis is an autoimmune disorder characterized by fluctuating muscle weakness and fatigue of different muscle groups, secondary to a synaptic transmission alteration caused by the blockade and destruction of the acetylcholine ...
Liubka María Pérez Mederos, María Ofelia Hernández Oliver, Cecilio González Benavides, José Manuel González Santos   +3 more
doaj  

Long‐Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis

Journal of the Peripheral Nervous System, Volume 31, Issue 3, September 2026.
ABSTRACT Background and Aims In ADHERE, subcutaneous efgartigimod PH20 (1000 mg once weekly) was effective and well tolerated in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). ADHERE+ is an open‐label extension of ADHERE assessing long‐term safety and efficacy. Methods Eligible participants from ADHERE run‐in period
Jeffrey A. Allen, Geoffrey Istas, Satoshi Kuwabara, Trevor Mole, Luis Querol, Simon Rinaldi, Mark Stettner, Benjamin Van Hoorick, Richard A. Lewis   +8 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, Volume 78, Issue 8, Page 1674-1686, August 2026.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Ofatumumab Treatment for Refractory Generalized Myasthenia Gravis Post‐Lung Adenocarcinoma Resection: A Case Report and Mechanistic Insight

Immunity, Inflammation and Disease, Volume 14, Issue 8, August 2026.
ABSTRACT Background Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may rarely coexist with malignancies such as lung cancer. Case Presentation This case report presents the first documented use of ofatumumab, a fully human anti‐CD20 monoclonal antibody, in a 75‐year‐old female with acetylcholine receptor (AChR)‐antibody‐positive ...
Xia Long, Yanwen Xu, Juan Xiong, Wenfeng Peng, Jinhua Qiu, Yanxia Zhou   +5 more
wiley   +1 more source

Trends in Clinical Indications for Plasma Exchange in Adult Patients Between 2008 and 2024 in Bogotá, Colombia

Journal of Clinical Apheresis, Volume 41, Issue 4, August 2026.
ABSTRACT This multicenter retrospective study aimed to describe temporal trends in clinical indications for plasma exchange (PE) in adult patients at four quaternary‐care hospitals in Bogotá (2008–2024) and to examine their distribution across successive ASFA guideline editions.
Edgar Julián Reyes, Federico Tovar‐Avendaño, Camilo Alberto Gonzalez‐Gonzalez, Diana Carolina Vargas‐Angel, Jorge Pulido, Paula Violeta Rodríguez, Deiner‐Yivelson Muñoz‐Delgado, Kateir Contreras‐Villamizar   +7 more
wiley   +1 more source

Modular Tissue‐Engineered Motor Units Featuring Spinal Motor Neurons Innervating Self‐Assembled Myofiber Bundles

Macromolecular Bioscience, Volume 26, Issue 8, August 2026.
The current study devised a methodology to biofabricate pre‐innervated, three‐dimensional bundled myofibers, as shown in this confocal micrograph depicting immunolabeled axons (red) and a multinucleated (blue) myofiber with well‐defined sarcomeres (green). ABSTRACT A motor unit is the functional unit of muscle contraction, consisting of a population of
Melanie C. Hilman, Elizabeth N. Krizman, Foteini Mourkioti, Suradip Das, D. Kacy Cullen   +4 more
wiley   +1 more source

Frontalis sling procedure for ocular myasthenia gravis

Clinical Ophthalmology, 2012
Shinichi Asamura1, Hirohiko Kakizaki2, Mitsuhiro Enjyo1, Takahiro Hashimoto1, Noritaka Isogai11Department of Plastic and Reconstructive Surgery, Kinki University School of Medicine, Osakasayama, Osaka, Japan; 2Department of Ophthalmology, Aichi Medical ...
Isogai N, Hashimoto T, Enjyo M, Kakizaki H, Asamura S   +4 more
doaj  

An Atypical Case of Myasthenia Gravis: Purely Bulbar in a Young Male

McGill Journal of Medicine, 2020
Myasthenia Gravis (MG), an uncommon autoimmune syndrome caused by the failure of neuromuscular transmission, results from bind- ing of autoantibodies to proteins that are involved in signaling at the neuromuscular junction (1).
Muhammad Amer Saleem, Faizan Pervaiz, Anum Yousaf, Muhammad Amer Saleem   +3 more
doaj